2024 ASCO® Annual Meeting Insights Hub

Meeting coverage & Vumedi’s exclusive highlights, all in one place.

 

ASCO® 2024 Insights: "Final OS & PFS From the AGO-OVAR 2.29/ENGOT-ov34 Study- Atezolizumab vs. Placebo in Combination With Bevacizumab + Chemo in Recurrent Ovarian Cancer"

By ecancer FEATURING Frederik Marmé
By ecancer FEATURING Frederik Marmé
83 views
June 21, 2024
Comments 0
Login to view comments. Click here to Login